JP2022519570A - 安定化Ｆｃ融合タンパク質溶液 - Google Patents

安定化Ｆｃ融合タンパク質溶液 Download PDF

Info

Publication number
JP2022519570A
JP2022519570A JP2021544796A JP2021544796A JP2022519570A JP 2022519570 A JP2022519570 A JP 2022519570A JP 2021544796 A JP2021544796 A JP 2021544796A JP 2021544796 A JP2021544796 A JP 2021544796A JP 2022519570 A JP2022519570 A JP 2022519570A
Authority
JP
Japan
Prior art keywords
aqueous solution
fusion protein
concentration
solution preparation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021544796A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020161487A5 (enExample
Inventor
ジェゼク ジャン
ジェリング デビッド
ハウエル サラ
Original Assignee
アレコル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレコル リミテッド filed Critical アレコル リミテッド
Publication of JP2022519570A publication Critical patent/JP2022519570A/ja
Publication of JPWO2020161487A5 publication Critical patent/JPWO2020161487A5/ja
Priority to JP2024174033A priority Critical patent/JP2025020122A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021544796A 2019-02-05 2020-02-05 安定化Ｆｃ融合タンパク質溶液 Pending JP2022519570A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024174033A JP2025020122A (ja) 2019-02-05 2024-10-03 安定化Ｆｃ融合タンパク質溶液

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1901547.8A GB201901547D0 (en) 2019-02-05 2019-02-05 Stabilized Fc Fusion protein solutions
GB1901547.8 2019-02-05
PCT/GB2020/050255 WO2020161487A1 (en) 2019-02-05 2020-02-05 STABILIZED Fc FUSION PROTEIN SOLUTIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024174033A Division JP2025020122A (ja) 2019-02-05 2024-10-03 安定化Ｆｃ融合タンパク質溶液

Publications (2)

Publication Number Publication Date
JP2022519570A true JP2022519570A (ja) 2022-03-24
JPWO2020161487A5 JPWO2020161487A5 (enExample) 2023-02-14

Family

ID=65996928

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544796A Pending JP2022519570A (ja) 2019-02-05 2020-02-05 安定化Ｆｃ融合タンパク質溶液
JP2024174033A Pending JP2025020122A (ja) 2019-02-05 2024-10-03 安定化Ｆｃ融合タンパク質溶液

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024174033A Pending JP2025020122A (ja) 2019-02-05 2024-10-03 安定化Ｆｃ融合タンパク質溶液

Country Status (5)

Country Link
US (1) US20220125718A1 (enExample)
EP (1) EP3921340A1 (enExample)
JP (2) JP2022519570A (enExample)
GB (1) GB201901547D0 (enExample)
WO (1) WO2020161487A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025084804A1 (ko) * 2023-10-18 2025-04-24 주식회사 엘지화학 Affimer의 안정화 제형 및 그의 제조 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517325A (ja) * 2010-01-19 2013-05-16 ハンミ サイエンス カンパニー リミテッド 持続型エリスロポエチン結合体の液剤
JP2016502528A (ja) * 2012-11-27 2016-01-28 アルテオジェン インコーポレイテッド タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物
JP2016518386A (ja) * 2013-05-02 2016-06-23 マブキシェンス エス．アー． ＴＮＦＲ：Ｆｃ融合ポリペプチドの代替配合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1478394T3 (da) 2002-02-27 2008-10-13 Immunex Corp Stabiliseret TNFR-Fc formulation med arginin
WO2012143418A1 (en) 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
AU2012279205B2 (en) 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
US10493151B2 (en) * 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US9649383B2 (en) * 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
JP6798882B2 (ja) * 2013-11-29 2020-12-09 アレス トレーディング ソシエテ アノニム ＴＮＦＲ及びＦｃ領域を含む融合タンパク質の液体製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517325A (ja) * 2010-01-19 2013-05-16 ハンミ サイエンス カンパニー リミテッド 持続型エリスロポエチン結合体の液剤
JP2016502528A (ja) * 2012-11-27 2016-01-28 アルテオジェン インコーポレイテッド タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物
JP2016518386A (ja) * 2013-05-02 2016-06-23 マブキシェンス エス．アー． ＴＮＦＲ：Ｆｃ融合ポリペプチドの代替配合物

Also Published As

Publication number Publication date
US20220125718A1 (en) 2022-04-28
JP2025020122A (ja) 2025-02-12
WO2020161487A1 (en) 2020-08-13
EP3921340A1 (en) 2021-12-15
GB201901547D0 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
JP7473603B2 (ja) 液体医薬組成物
AU2013255413B2 (en) Pharmaceutical formulations of TNF-alpha antibodies
RU2600847C2 (ru) Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
JP7208302B2 (ja) 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物
JP7220664B2 (ja) 液体医薬組成物
KR102413592B1 (ko) 약학적 제형 및 그의 제조 방법
JP7357540B2 (ja) 液体医薬組成物
JP2025163108A (ja) 抗ＩＬ－２３ｐ１９抗体製剤
JP2022105056A (ja) 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
JP2025020122A (ja) 安定化Ｆｃ融合タンパク質溶液
KR20240053633A (ko) Vegf 수용체 융합 단백질을 위한 제제
JPWO2017164349A1 (ja) ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物
CA3152838A1 (en) Novel formulation of highly concentrated pharmacologically active antibody
WO2023126411A1 (en) Vedolizumab formulation
JP2022544216A (ja) 抗体を含む新規組成物
AU2020207124A1 (en) Pharmaceutical composition comprising antibody, device comprising same, and use thereof
JP2024507347A (ja) Ｆｃドメインを含む操作されたタンパク質コンストラクトの水性組成物
TWI771335B (zh) 穩定藥學調配物
KR20250155050A (ko) ActRIIa 단백질 변이체를 포함하는 제제
BR112019007858B1 (pt) Composições farmacêuticas, métodos relacionados, kit, recipiente de dose única e uso
HK40010132A (en) AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNFα
HK40010132B (zh) 重组单克隆抗TNF α 抗体的水性药用组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241121

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250827